OLMA Olema Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OLMA

Price (delayed)

$10.51

Market cap

$919.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.13

Enterprise value

$874.66M

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 46
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5
Highlights
The debt has declined by 23% year-on-year and by 7% since the previous quarter
Olema Pharmaceuticals's equity has increased by 25% YoY but it has decreased by 10% from the previous quarter
Olema Pharmaceuticals's net income has decreased by 44% YoY and by 10% from the previous quarter
OLMA's quick ratio is down by 20% year-on-year and by 19% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER VIVS ORIC ORMP

Key stats

What are the main financial stats of OLMA

OLMA stock price

How has the Olema Pharmaceuticals stock price performed over time
Intraday
0.67%
1 week
-10.93%
1 month
-11.31%
1 year
99.43%
YTD
-57.96%
QTD
-15.99%

Financial performance

How have Olema Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$221.13M
Net income
-$204.57M
Gross margin
N/A
Net margin
N/A
Olema Pharmaceuticals's net income has decreased by 44% YoY and by 10% from the previous quarter
The operating income has decreased by 41% YoY and by 10% QoQ

Price vs fundamentals

How does OLMA's price correlate with its fundamentals

Growth

What is Olema Pharmaceuticals's growth rate over time

Valuation

What is Olema Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.13
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OLMA's EPS is down by 14% YoY and by 4.9% QoQ
Olema Pharmaceuticals's equity has increased by 25% YoY but it has decreased by 10% from the previous quarter
OLMA's price to book (P/B) is 24% less than its last 4 quarters average of 2.8 but 12% more than its 5-year quarterly average of 1.9

Efficiency

How efficient is Olema Pharmaceuticals business performance
Olema Pharmaceuticals's ROE has decreased by 13% YoY and by 5% from the previous quarter
The return on assets has declined by 11% year-on-year and by 4.4% since the previous quarter
The return on invested capital has declined by 4.1% since the previous quarter

Dividends

What is OLMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OLMA.

Financial health

How did Olema Pharmaceuticals financials performed over time
Olema Pharmaceuticals's total liabilities has soared by 52% YoY and by 12% from the previous quarter
Olema Pharmaceuticals's total assets has increased by 27% YoY but it has decreased by 8% from the previous quarter
The debt is 99% smaller than the equity
Olema Pharmaceuticals's equity has increased by 25% YoY but it has decreased by 10% from the previous quarter
The debt has declined by 23% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.